Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease-Reference-Cited by-同舟云学术

Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease

Published:2012-12 Issue:4 Volume:2 Page:S17-S26
ISSN:2210-5336
Container-title:Basal Ganglia
language:en
Short-container-title:Basal Ganglia

Author:

Jost Wolfgang H.,Friede Michael,Schnitker Jörg

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference48 articles.

1. Diener HC, Putzki N. Leitlinien der Deutschen Gesellschaft für Neurologie. 5. überarbeitete Auflage. Stuttgart, New York: Thieme;2012.

2. DeLong MR, Juncos JL. Chapter 366. Parkinson’s disease and other extrapyramidal movement disorders. In: Fauci AS, Braunwald E, Kasper DL et al., editors. Hrsg. Harrison’s Online McGraw-Hill: accessed Oct 24th 2010.

3. Hrsg. Goodman and Gilman’s manual of pharmacology and therapeutics;Brunton,2007

4. The role of rasagiline in the treatment of Parkinson’s disease;Leegwater-Kim;Clin Interv Aging,2010

5. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease;Olanow;N Engl J Med,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology;Journal of Neurology;2024-08-29

2. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis;Frontiers in Aging Neuroscience;2023-04-11

3. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach;Expert Review of Neurotherapeutics;2023-01-02

4. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies;International Journal of Molecular Sciences;2022-09-21

5. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease;Journal of Neural Transmission;2022-02-02